Device Cardiac Rhythm Management

Allure Quadra

Payments companies reported to CMS as associated with Allure Quadra. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$29Kassociated payments (2023-2025)
273clinicians with associated payments
1company reporting

By year

2023 $22K
2024 $4,730
2025 $2,368

Payments reported as associated with Allure Quadra, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Clinical Cardiac Electrophysiology $16K
Thoracic Surgery (Cardiothoracic Vascular Surgery) $4,373
Cardiovascular Disease $2,517
Internal Medicine $1,883
Interventional Cardiology $912
Family $713

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Allure Quadra

These are the largest totals companies reported as associated with Allure Quadra. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Brian Kim Kearney, NE Clinical Cardiac Electrophysiology $11,024.65
Lawrence Durban West Islip, NY Thoracic Surgery (Cardiothoracic Vascular Surgery) $3,920.31
Yoel Vivas Delray Beach, FL Clinical Cardiac Electrophysiology $500.00
Zachary Estep Browns Mills, NJ Internal Medicine $381.52
Saumya Sharma Humble, TX Clinical Cardiac Electrophysiology $306.22
James Barnett Midland, TX Cardiovascular Disease $219.01
Sidney Peykar Port Charlotte, FL Clinical Cardiac Electrophysiology $210.30
Francis Le Panama City, FL Clinical Cardiac Electrophysiology $210.19
Mary Lim-Fung Humble, TX Clinical Cardiac Electrophysiology $207.52
Mark Heckle Cordova, TN Clinical Cardiac Electrophysiology $196.95

Prescribed Allure Quadra?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.